Compare Essex Property Trust, Inc. (ESS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs TG Therapeutics Inc — how do they compare? Essex Property Trust, Inc. trades at $297.27 (market cap $18.82B), while TG Therapeutics Inc trades at $54.91 (market cap $8.64B). The key difference: Essex Property Trust, Inc. is far larger — about 2.2× TG Therapeutics Inc's market cap, and Essex Property Trust, Inc. pays a 3.54% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ESS | TGTX | |
|---|---|---|
Market Cap | $18.82B | $8.64B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $59.06 |
52-Week Low | $239.61 | $26.39 |
Enterprise Value | $25.54B | $8.88B |
Dividend Yield | 3.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $297.29, down slightly by 0.28% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results expected soon. Fundamentals show robust profitability with a 30.03% net income margin and $669.67M net income for 2025, though valuation ratios like a P/E of 32.93 appear elevated. Recent news highlights sustainability initiatives and inclusion in the Russell Microcap Index.
The outlook for ESS is cautiously optimistic, supported by high West Coast rental demand and AI-driven employment growth. Risks include elevated debt levels and Seattle market weakness. Analysts are mixed with a $294.25 consensus price target, slightly below the current price, suggesting limited near-term upside amid solid operational performance.
TG Therapeutics (TGTX) trades at $56.20, up 2.39% on the day, with a bullish technical signal and strong analyst consensus (84.6% buy ratings). The stock's momentum is supported by robust revenue growth, with 2025 revenue reaching $616.29M and net income of $447.18M, yielding impressive profitability margins (Gross Margin: 83.05%, ROE: 112.6%). Recent positive clinical updates for Briumvi in multiple sclerosis and schizophrenia trials have fueled investor optimism and media coverage.
The outlook remains positive due to Briumvi's commercial expansion and pipeline progress, though risks include earnings volatility (two recent misses), high valuation multiples (EV/EBITDA: 59.1), and clinical trial dependencies. The current price sits above the consensus price target of $48.50, suggesting near-term valuation concerns may limit upside unless operational execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
